Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Target Price
The average target price of STRO is 20 and suggests 20% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Buy
Sell